[
  {
    "ts": "2026-01-24T03:58:58+00:00",
    "headline": "Oppenheimer Questions Valuation of Boston Scientific’s $14.5 Billion Penumbra Deal",
    "summary": "Boston Scientific Corporation (NYSE:BSX) is one of the best mid-cap growth stocks to buy right now. On January 16, Oppenheimer lowered its price target on Boston Scientific to $100 from $125 with an Outperform rating. Oppenheimer is cautious on the financial optics of Boston Scientific’s $14.5 billion acquisition of Penumbra. Although the deal creates a […]",
    "url": "https://finance.yahoo.com/news/oppenheimer-questions-14-5b-penumbra-025258409.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "3661ef5f-015e-3a3b-9927-092fcc2afae2",
      "content": {
        "id": "3661ef5f-015e-3a3b-9927-092fcc2afae2",
        "contentType": "STORY",
        "title": "Oppenheimer Questions Valuation of Boston Scientific’s $14.5 Billion Penumbra Deal",
        "description": "",
        "summary": "Boston Scientific Corporation (NYSE:BSX) is one of the best mid-cap growth stocks to buy right now. On January 16, Oppenheimer lowered its price target on Boston Scientific to $100 from $125 with an Outperform rating. Oppenheimer is cautious on the financial optics of Boston Scientific’s $14.5 billion acquisition of Penumbra. Although the deal creates a […]",
        "pubDate": "2026-01-24T03:58:58Z",
        "displayTime": "2026-01-24T03:58:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/45f2400d2f7f0dd44fd960cafcbec175",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Oppenheimer Questions $14.5B Penumbra Deal Valuation Despite Boston Scientific’s (BSX) Mew Market Dominance",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pPbu5IVWFLzFUIu5nzLVlg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/45f2400d2f7f0dd44fd960cafcbec175.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jAxutOZAcJj.3HgLdpxDDQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/45f2400d2f7f0dd44fd960cafcbec175.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/oppenheimer-questions-14-5b-penumbra-025258409.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/oppenheimer-questions-14-5b-penumbra-025258409.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BSX"
            },
            {
              "symbol": "PEN"
            },
            {
              "symbol": "SYK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]